EUCTR2010-021196-85-IS进行中（未招募）1 期
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer - PROSPECT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Signed Informed Consent
- •2.Men, =18 years of age with documented asymptomatic or minimally
- •symptomatic metastatic castration-resistant prostate cancer.
- •3. Castrate testosterone level < 50 ng/dl
- •4. Documented progressive disease post-surgical castration or during
- •androgen suppression therapy or during complete androgen blockade
- •therapy and withdrawal. Documented by either criterion a (Radiological
- •progression), OR criterion b (PSA progression).
- •a. Radiological progression defined as any new/enlarging bone
- •mestatases or new/enlarging lymph node disease, consistent with
- •prostate cancer.
- •b. PSA progression defined by sequence of rising values separated by >
- •1 week (2 separate increasing values) over a threshold minimum of 2.0
- •ng/ml. (PCWG2 PSA eligibility criteria).
- •5. Chemotherapy naïve. No prior chemotherapy for metastatic prostate
- •cancer. Neo-adjuvant or adjuvant chemotherapy for primary prostate
- •cancer is permissible if >3 years prior.
- •6. Vaccinia-experienced (previous smallpox vaccination).
- •7. ECOG Performance Score of 0 or 1.
- •8. Life expectancy = 1 year.
- •9. Bone Marrow function:
- •- Absolute neutrophil count = 1,500/mm3
- •- Hemoglobin = 10 g/dL
- •- Platelet count = 100,000/mm3
- •10. Hepatic Function:
- •- AST and ALT = 2.5 times upper limit of normal (ULN)
- •- Bilirubin = 1.5 times ULN
- •11. Renal Function:
- •- Creatinine = 2.0 times ULN
- •12. Currently using a GnRH agonist or antagonist (unless surgically
- •castrated).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 900
排除标准
- •1. Cancer-related pain requiring scheduled opioid narcotics for control (as needed. = 2x per week is allowed).
- •2. Metastasis to organ systems other than lymph nodes and/or bone.
- •3. LDH = 2 times ULN.
- •4. Alkaline phosphatase = 2 times ULN.
- •5. Estimated PSA doubling time of <1 month as established within 6 months of the anticipated first dose of vaccine or placebo. A minimum of 3 PSA level determinations, at least 2 weeks apart (over a 6 month timeperiod), are required for assessment.
- •6. Concurrent or prior Provenge (sipuleucel-T) immunotherapy for prostate cancer
- •7. Receipt of an investigational agent within 30 days (or 60 days for an antibody-based therapy) of the first planned dose of PROSTVAC-V/F. There is no exclusion to previous experimental therapy provided dosing/treatment is completed at least 30 days prior to the first planned dose of vaccine unless otherwise noted.
- •8. History of prior malignancies other than prostate cancer within the past 3 years, excluding successfully resected basal or squamous cell carcinoma of the skin
- •9. Congestive heart failure (NYHA Class II, III, or IV), unstable angina, ventricular or hemodynamically significant atrial arrhythmia, or cardiovascular disease such as stroke or myocardial infarction (current or within the past 6 months).
- •10. Confirmed positive for HIV, hepatitis B, and /or hepatitis C.
- •11. Prior solid organ or bone marrow transplant
- •12. Immunodeficiency or splenectomy
- •13. Chronic immunosuppressive therapy within 30 days of screening.
- •14. Inflammatory eye disease requiring steroid treatment.
- •15. Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days of
- •the first planned dose of PROSTVAC-V/F. Use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed.
- •16. History of or active autoimmune disease (e.g. autoimmune neutropenia, thrombocytopenia, or hemolytic anemia, systemic lupus erythematosis, Sjogren?s syndrome, scleroderma, myasthenia gravis, Goodpasture?s syndrome, Addison?s disease, Hashimoto?s thyroiditis, or Graves disease). Persons with vitiligo are not excluded. Diabetics are not excluded if the condition is well controlled.
- •17. Known allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin), or GM-CSF. Subjects with a known or suspected allergy to radiological contrast agents are eligible, but this must be noted in the subject's medical history and in the chart notes.
- •18. History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis.
- •19. Previous adverse reactions to smallpox vaccination.
- •20. Unable to avoid close contact or household contact with the following high-risk individuals for three to four weeks after the Day 1 vaccination or until the vaccination site heals completely: (a) children ? 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV.
- •21. Significant medical abnormality (defined as a pre-existing condition AE/condition = Grade 3 according to NCI CTCAE v 4.0 and any condition which, in the opinion of the investigator, would prevent full participation in this trial (including the Long-Term Follow-Up), or would interfere with the evaluation of the trial endpoints.
- •22. Study personnel.
研究者
相似试验
招募中
1 期
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).CTIS2023-506669-70-00Alexion Pharmaceuticals Inc.982
进行中（未招募）
1 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCCResectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001974-76-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Recurrent, Platinum-Sensitive Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005099-21-NOMersana Therapeutics, Inc.581
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to study the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageAcute Migraine (with or without aura)MedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005246-15-PLPfizer Inc.640
进行中（未招募）
1 期
Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormalityMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2021-000761-33-PLKronos Bio, Inc.180